Nurix Therapeutics, Inc. NRIX
NASDAQ
| 08/31/2026 | 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 294.88M | -341.35M | -295.28M | -264.46M | -244.79M |
| Total Depreciation and Amortization | 15.27M | 16.66M | 17.90M | 18.26M | 17.23M |
| Total Amortization of Deferred Charges | 600.00K | 600.00K | 600.00K | 600.00K | 1.30M |
| Total Other Non-Cash Items | 34.56M | 32.30M | 30.15M | 27.73M | 25.47M |
| Change in Net Operating Assets | 34.00M | -1.91M | -13.67M | -31.60M | -29.60M |
| Cash from Operations | 379.31M | -293.70M | -260.29M | -249.47M | -230.38M |
| Capital Expenditure | -9.50M | -10.82M | -11.56M | -14.00M | -10.98M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 10.60M | 30.82M | 10.06M | 161.86M | 17.67M |
| Cash from Investing | 1.10M | 19.99M | -1.51M | 147.85M | 6.69M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 261.21M | 257.20M | 257.14M | 238.64M | 203.16M |
| Repurchase of Common Stock | -- | -- | -- | -- | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 261.21M | 257.20M | 257.14M | 238.64M | 203.16M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 641.62M | -16.51M | -4.65M | 137.03M | -20.54M |